TRBC1 and T-cell non-Hodgkin lymphoma: The dysregulation of the mTORC2 pathway is further validated by the observed down-regulation of TCR components (TRAC, TRBC1) and stabilizing molecules (TRAT1) seen across multiple T-cell lymphoma subtypes (S1 Table).